MedTrace Logo

Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)

NCT00666016 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-12-18

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, the tolerability and the short term effect on liver enzymes of TRO19622 500 mg for one month in patients with Non-Alcoholic Steatohepatitis (NASH).

Conditions

  • Non-Alcoholic Steatohepatitis (NASH)

Interventions

DRUG

TRO19622

TRO19622 500 mg once a day before noon meal during 6 weeks

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Vlad Ratziu, MD · GH PITIE-SALPETRIERE

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-15
Primary Completion
2009-02-05
Completion
2009-02-05

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00666016 on ClinicalTrials.gov